Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflammatory Biomarkers in Blood and CSF in Alzheimer's Disease
NCT00715858Phase 3Unknown
- Sponsor
- McMaster University
- Start
- May 2008
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doxycycline and rifampicin in Alzheimer's disease (AD) (5 arms), sponsored by McMaster University. Primary endpoints: Interleukin-1 beta at 12 months, Tumor Necrosis Factor alpha at 12 months and 3 more. Status: unknown.
02
Drugs
doxycyclinerifampicin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00715858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00715858.